Need Help With This Product?
Our specialists are here to help you find the best product for your application.
iCell DopaNeurons PD LRRK2 G2019S, 11299 and Isogenic Control
Product Overview
Mutations in leucine-rich repeat kinase-2 (LRRK2) is an associated risk factor for both familial and sporadic Parkinson’s disease (PD). The LRRK2 kinase is expressed in the brain and is thought to be involved in vesicular trafficking, neurite outgrowth, and protein degradation. The LRRK2 G2019S mutation, the predominant variant associated with PD, is within the kinase domain resulting in elevated kinase activity.
iCell® DopaNeurons PD LRRK2 were derived from induced pluripotent stem (iPS) cells from the Parkinson's Progression Markers Initiative (PPMI). Sponsored by The Michael J. Fox Foundation, PPMI partnered with FUJIFILM Cellular Dynamics (FCDI) to produce a large bank of Parkinson’s donor-derived iPS cells, including lines harboring Parkinson’s-associated genetic mutations, such as LRRK2 G2019S. Each cell line is supported by PPMI donor clinical, imaging, genomics, and biological data. (www.ppmi-info.org)
To enable investigation of the functional consequences of the mutation within this patient-derived line, we used genetic engineering to generate a G2019S/G mutation-corrected isogenic cell line from the same donor.
iCell DopaNeurons lines are differentiated into human midbrain floorplate dopaminergic (DA) neurons according to protocols licensed and adapted from the Lorenz Studer lab (Memorial Sloan Kettering) and industrialized at FCDI.
Benefits of iCell DopaNeurons PD LRRK2 G2019S and isogenic LRRK2 G2019S/G cell lines:
- Fully differentiated, >80% pure midbrain DA neurons derived from LRRK2 G2019s donor iPS cells
- Express midbrain dopaminergic neuron markers (e.g., Lmx1, FoxA2, and TH)
- Isogenic control LRRK2 G2019S/G mutation-corrected cell line is available.
- iCell DopaNeurons PD LRRK2 G2019S exhibit:
- Altered dopamine metabolism
- Elevated alpha-synuclein protein accumulation
- Increased neuronal degeneration compared to the apparently healthy normal control iCell DopaNeurons
- Reduced GCase activity
- Accessible and consistent model for discovery and toxicology research of Parkinson’s disease
- View all Parkinson’s Disease iCell DopaNeurons cell lines
Components:
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Technical Docs
PROTOCOLS
Application Protocols
Immunofluorescent Labeling of iCell DopaNeurons
Application Protocols
Using Liposome-mediated Transfection for Gene Delivery - iCell DopaNeurons
USER DOCS
User's Guides
iCell DopaNeurons User's Guide
Biosafety Document
iCell DopaNeurons G2019S/G Mutation-corrected Control Biosafety Document
Safety Data Sheet
iCell Neural Supplement B Safety Data Sheet
Safety Data Sheet
iCell Nervous System Supplement Safety Data Sheet
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet - Asia
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet
Safety Data Sheet
iCell Neural Base Medium 1 Safety Data Sheet
Performance Data
Applications
- Drug targeted screening
- Neurotoxicology
- Parkinson’s disease modeling
- Gaucher’s disease modeling
Product Highlights
Easy to implement
Shipped cryopreserved with optimized media. Simply thaw and use.
High throughput
Available in multiple unit sizes to support both scalable research and drug screening programs.
Consistent culture
80% tyrosine hydroxylase (TH)-positive dopaminergic neurons provides a robust and reproducible cell culture system.
Backed by clinical data
Generated in partnership with the PPMI and supported by patient clinical information. Visit PPMI for more information.
Biologically relevant
Derived from Parkinson’s Disease donor material and selected for common disease-associated gene mutations.
Publications
Citing of GBA and LRRK2 iCell DopaNeurons in Publications Publications and presentations featuring GBA and LLRK2 iCell DopaNeurons should reference the Parkinson's Progression Markers Initiative (PPMI) and the Golub Capital iPSC PPMI Sub-study (www.ppmi-info.org) as the original iPS cell line(s) source for the differentiated cells used in these experiments. Publications should acknowledge that the Parkinson's Progression Markers Initiative (PPMI) is a public-private partnership funded by The Michael J. Fox Foundation for Parkinson’s Research and other funding partners. Publications using these cells should be made available without charge to the research community through the PPMI website, when not prohibited by publication copyright terms and conditions. For assistance in uploading to the PPMI website, please contact: https:/www.ppmi-info.org/contact-us/. ()